USPTO serial 79066733
CHARIOTEER
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 8, 2009
- Examiner
- LEE, DEBRA ANN
- Law office
- GENERIC WEB UPDATE
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with CHARIOTEER?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
ZHEJIANG CHARIOTEER; PHARMACEUTICAL CO.LTD
Taizhou, CN
Other trademarks owned by ZHEJIANG CHARIOTEER; PHARMACEUTICAL CO.LTD
ZHEJIANG CHARIOTEER; PHARMACEUTICAL CO.LTD
CN
Other trademarks owned by ZHEJIANG CHARIOTEER; PHARMACEUTICAL CO.LTD
ZHEJIANG CHARIOTEER; PHARMACEUTICAL CO.LTD
CN
Other trademarks owned by ZHEJIANG CHARIOTEER; PHARMACEUTICAL CO.LTD
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Antipyretyc, analgesic and anti-inflammatory active pharmaceutical ingredient, namely, naproxen, naproxen sodium, naproxen celecoxib, nimesulide, aceclofenac, sulindac, ibuprofen, fenoprofen, ketoprofen, celecoxib, nimesulide, aceclofenac; anti-inflammatory active pharmaceutical ingredient, namely, naproxen nitroxyalkylesters; antipyretic and analgesic active pharmaceutical ingredient, namely, aspirin, acetaminophen, propyphenazone; antipyretic and analgesic, antithrombotic active pharmaceutical ingredient, namely, indomethacin; analgesic active pharmaceutical ingredient, namely, eptazocine, ketorolac tromethamine; antipyretic, analgesic active pharmaceutical ingredient, namely, propyphenazone; anti-inflammatory and anti-virus active pharmaceutical ingredient, namely, amantadine hydrochloride; treating rheumatoid arthritis active pharmaceutical ingredient, namely, flurbiprofen, meloxicam, phenylbutazone; anti-platelet aggregation active pharmaceutical ingredient, namely, clopidogrel hydrogen sulfate; anti-platelet drugs active pharmaceutical ingredient, namely, prasugrel; anti-cancer active pharmaceutical ingredient, namely, topotecan hydrochloride, ifosfamide, mesna, irinotecan, camptothecin, 7-ethyl-10-hydrol-camptothecin, docetaxel; treating iodine deficiency active pharmaceutical ingredient, namely, iodine; anti-goitre expectoration and active pharmaceutical ingredient, namely, potassium iodide; treating supraventricular arrhythmia, typical angina and variant angina active pharmaceutical ingredient, namely, diltiazem; anti-hepatitis B virus active pharmaceutical ingredient, namely, adefovir dipivoxil, lamivudine, telbivudine, clevudine; anti-urogenital system disease active pharmaceutical ingredient, namely, phenazopyridine hydrochloride; anti-virus active pharmaceutical ingredient, namely, acyclovir, acyclovir sodium, penciclovir, zidovudine, ganciclovir, ganciclovir sodium, famciclovir, valaciclovir hydrochloride, valganciclovir hydrochloride, ribavirin, 6-deoxyacyclovir, polyinosinic polycytidylic acid, interferons, adenine, farmivisen, docosanol, zanamvir, oseltamivir, indinavir, ritonavir, nelfinavir, delavirdine, efavirenz, ainprenavir, lopinavir, cidofovir, imiquimod, didanosine, foscarnet sodium, penciclovir sodium, stavudine, abacavir, tenofovir disoproxil, emdtricitabine, brivudine, amprenavir, rimantadine; expectorant active pharmaceutical ingredient, namely, fudosteine, carbocisteine; anti-hypertension active pharmaceutical ingredient, namely, valsartan, losartan, irbesartan, tasosartan, candesartan, telmisartan, eprosartan, olmesartan; anxiolytic active pharmaceutical ingredient, namely, brofoxine; treating coronary heart disease active pharmaceutical ingredient, namely, dipyridamole; immunosuppressive active pharmaceutical ingredient, namely, tacrolimus; immunosuppressive agents active pharmaceutical ingredient, namely, sirolimus; treating cardiac and cerebrovascular disease active pharmaceutical ingredient, namely, nicergoline; treating coronary heart disease active pharmaceutical ingredient, namely, isosorbide mononitrate; anti-obesity active pharmaceutical ingredient, namely, orlistat; antipsychotic active pharmaceutical ingredient, namely, perazine maleate, carisoprodol; anti-leprosy disease active pharmaceutical ingredient, namely, thalidomide; anti-vitamin deficiency active pharmaceutical ingredient, namely, folic acid, dexpanthenol; anti-megaloblastic anemia active pharmaceutical ingredient, namely, calcium levofolinate; antithrombotic active pharmaceutical ingredient, namely, ticlopidine hydrochloride; anti-rejection active pharmaceutical ingredient, namely, rapamycin, mizoribine, mycophenolic acid, mycophenolate mofetil, mycophenolate sodium, clarithromycin, daptomycin, mupirocin, ertapenem, doripenem, biapenem, meropenem, imipenem, faropenem, aztreonam, benflumetol, mupirocin, caspofungin; treating diabetes mellitus active pharmaceutical ingredient, namely, metformin, voglibose; antioxidant, treatment heart disease and anti-hypertension active pharmaceutical ingredient, namely, coenzyme Q10; treating brain edema and glaucoma active pharmaceutical ingredient, namely, isosorbide; anti-aids active pharmaceutical ingredient, namely, nevirapine | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ZHEJIANG CHARIOTEER; PHARMACEUTICAL CO.LTD
- Other trademarks owned by ZHEJIANG CHARIOTEER; PHARMACEUTICAL CO.LTD
- Other trademarks owned by ZHEJIANG CHARIOTEER; PHARMACEUTICAL CO.LTD
- Other trademarks in Class 005
- Similar marks named CHARIOTEER
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 30, 2019 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Jul 30, 2019 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| Jul 26, 2019 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 26, 2019 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Dec 28, 2018 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Dec 8, 2018 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Jan 15, 2015 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Jan 15, 2015 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| Jan 15, 2015 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Dec 11, 2014 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Dec 11, 2014 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 30, 2013 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Apr 1, 2010 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 1, 2010 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 9, 2010 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 8, 2009 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 22, 2009 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 2, 2009 | NPUB | NOTICE OF PUBLICATION | — |
| Aug 18, 2009 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Aug 18, 2009 | ALIE | ASSIGNED TO LIE | — |
| Aug 11, 2009 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 20, 2009 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 15, 2009 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 15, 2009 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 22, 2009 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 27, 2009 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 27, 2009 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 26, 2009 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 25, 2009 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 21, 2009 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 17, 2009 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 17, 2009 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 16, 2009 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |